SMEs learn more about how to commercialise health related products at Lifescience Launchpad

Size: px
Start display at page:

Download "SMEs learn more about how to commercialise health related products at Lifescience Launchpad"

Transcription

1 Innovation Nexus Case Study 3 SMEs learn more about how to commercialise health related products at Lifescience Launchpad

2 With such a diverse cohort of companies spanning drug development, diagnostics and medical devices it was interesting to witness the participants engagement and evident learning throughout the programme Diane Cresswell, Executive Director of Business Development, Bionow A cohort of nine Northwest SMEs, including seven based within the footprint of Greater Manchester Academic Health Science Network (GM AHSN) took part in a unique programme to help them understand more about commercialising their health-related products and services. The Lifescience Launchpad event was organised by Bionow as part of GM AHSN s business engagement programme, which aims to build the best support structure for SMEs who wish to work with us to develop and deliver new innovations into the NHS. Bionow is a not for profit membership organisation for the biomedical / life-sciences industry in the North of England and supports business growth, competitiveness and innovation. The SMEs, listed further down, covered various topics including market research, health economics, developing products to meet specific unmet needs, NHS procurement and how to sell to the NHS, grant and seed funding among others. How it happened Bionow recruited nine companies, all of which are already developing products and services of direct relevance to the NHS, to take part in the programme. Each SME completed a business diagnostic with Bionow in order to gauge future requirements and support needed as part of the three-month programme.

3 Bionow The attendees were all very experienced in their respective fields but clearly all had much to learn with regard to engaging with the NHS Diane Cresswell, Executive Director of Business Development, Bionow Bionow focuses upon the specific needs of firms at their different stages of development, including dedicated business support programmes, shared procurement schemes with significant cost savings, exclusive insurance benefits, recruitment and training services, local and national events and access to a vibrant network of businesses. Members include start-ups and early stage firms as well as established growthorientated companies there are more than 250 members including corporate sponsor AstraZeneca and university sponsors Manchester, Liverpool, Lancaster, Newcastle, Durham, Sunderland and Leeds. Visit Innovation Nexus GM AHSN has a specific focus on helping SMEs to develop their products and support the spread of innovation at scale within the NHS. The Launchpad is one of a number of support initiatives we are bringing to Greater Manchester SMEs Linda Magee, Executive Director of Industry and Wealth, GM AHSN Focused on supporting SMEs to do business with the NHS, the GM AHSN has established the Innovation Nexus as a bespoke support system for med-tech in the Greater Manchester region. Supported by 34 member organisations and a range of influential partners, including TRUSTECH, Innovation Nexus acts as a one-stop access hub from which companies can access information, funding opportunities and expertise as well as procurement help. Its current primary priority clinical areas are cardiovascular health, patient safety and digital health/informatics. Visit

4 Participating SME profiles Blueberry Therapeutics employs cutting-edge nanopolymer drug delivery technology in developing treatments in the areas of infection and inflammation where there is a high-unmet medical need. Its lead product BB0305, a novel nanoparticle antifungal formulation for the topical treatment of onychomycosis, will enter Phase 3 trials in C-Major has designed and trialled the world s first controlled retraction hypodermic device system that meets the aim of clinicians to reduce the number of needle stick injuries globally. The company is now completing the design and is looking to establish production and device approvals for entry into the fastest growing segment of the $3bn safety syringe market by Galen Research Limited is a leading international developer of Patient Reported Outcome (PRO) measures for use in clinical trials, health economic studies and routine clinical practice. The company has an established reputation for high quality work with the major UK, European and US pharmaceutical companies. Gelexir Healthcare is introducing a novel, non-surgical procedure for the treatment of chronic lower back pain caused by degenerative disc disease. Imagen Biotech is developing a technology (high content screening) to allow oncologists to personalise chemotherapy and thus select the best treatment for each patient. Lumbacurve International Ltd has designed and manufactured an innovative low back pain relief device. Recent independent clinical trials have shown it to be significantly more effective than current standard treatment guidelines. Newtec Vascular Technology Ltd develops cardiovascular medical devices. Newtec is currently preparing to commence a clinical study on its first product for prevention of vascular stenosis (blood vessel narrowing). The device is simple and quick to fit at the time of surgery with minimal deviation from existing clinical practice. Optasia Medical uses novel image analysis techniques to extract clinically relevant information from medical images to better inform patient treatment. Physicians can then make better-informed decisions in managing patients suffering from musculoskeletal diseases, especially in the elderly. Sensam has developed a point-of-care breath test system to aid diagnosis of a range of illnesses. The current focus is on the diagnosis of a common stomach infection and the trials in clinical environments are currently under way. Further work has just started on fine-tuning of the Sensam system for the lung cancer detection and screening.

5 How to get IN touch? It s easy to access our expert advice service: Go to /gm-ahsn-advisors Then click on the link saying Access the enquiry system - this will take you to the registration page where you can create an account and fill in the enquiry questionnaires.

Med-tech and diagnostic device pathways in Newcastle

Med-tech and diagnostic device pathways in Newcastle Med-tech and diagnostic device pathways in Newcastle Andrew Sims Medical Physics Newcastle upon Tyne Hospitals NHS Foundation Trust 12/07/2016 AHSN Stakeholder Engagement Meeting 1 Introduction Section

More information

Greater Manchester Health and Social Care Strategic Partnership Board

Greater Manchester Health and Social Care Strategic Partnership Board Greater Manchester Health and Social Care Strategic Partnership Board 9 Date: 13 October 2017 Subject: Report of: Health Innovation Manchester Update on Progress Rowena Burns, Executive Chair, Health Innovation

More information

LEEDS CITY REGION DIAGNOSTICS AND PERSONALISED MEDICINE

LEEDS CITY REGION DIAGNOSTICS AND PERSONALISED MEDICINE LEEDS CITY REGION DIAGNOSTICS AND PERSONALISED MEDICINE LEEDS CITY REGION S STRENGTHS: LIFE SCIENCES - THE OPPORTUNITY TAP INTO WORLD-LEADING RESEARCH FROM LEEDS CITY REGION S UNIVERSITIES ACCELERATING

More information

Supporting efficient and effective clinical research in the UK

Supporting efficient and effective clinical research in the UK Supporting efficient and effective clinical research in the UK National Institute for Health Research 10 years of delivering health and care research for the nation HRB CRCI Launch Dr Matthew Hallsworth

More information

Delivering the NIHR Central Commissioning Facility

Delivering the NIHR Central Commissioning Facility Delivering the NIHR Central Commissioning Facility About the NIHR The National Institute for Health Research is funded through the Department of Health to improve the health and wealth of the nation through

More information

Invitation to Quote. Associate Digital Infrastructure Support Provision. March Associate Digital Infrastructure Support Provision Page 1 of 5

Invitation to Quote. Associate Digital Infrastructure Support Provision. March Associate Digital Infrastructure Support Provision Page 1 of 5 Invitation to Quote Associate Digital Infrastructure Support Provision March 2018 Associate Digital Infrastructure Support Provision Page 1 of 5 Introduction The aim of this document is to select and appoint

More information

NIHR Invention for Innovation Workshop. Leeds Clinical Research Facility Adding Value Debbie Beirne NIHR Leeds CRF Manager

NIHR Invention for Innovation Workshop. Leeds Clinical Research Facility Adding Value Debbie Beirne NIHR Leeds CRF Manager NIHR Invention for Innovation Workshop Leeds Clinical Research Facility Adding Value Debbie Beirne NIHR Leeds CRF Manager Integrated R&I Model Surgical MedTech (MIC) CRF R&I In Vitro Diagnostics (MIC)

More information

THE UNIVERSITY OF MANCHESTER PARTICULARS OF APPOINTMENT FACULTY OF BIOLOGY, MEDICINE & HEALTH SCHOOL OF BIOLOGICAL SCIENCES

THE UNIVERSITY OF MANCHESTER PARTICULARS OF APPOINTMENT FACULTY OF BIOLOGY, MEDICINE & HEALTH SCHOOL OF BIOLOGICAL SCIENCES THE UNIVERSITY OF MANCHESTER PARTICULARS OF APPOINTMENT FACULTY OF BIOLOGY, MEDICINE & HEALTH SCHOOL OF BIOLOGICAL SCIENCES HEALTH INNOVATION MANCHESTER SENIOR PROGRAMME MANAGER (PRECISION MEDICINE) VACANCY

More information

Healthcare. Healthcare. The Centre for Process Innovation. From innovation to commercialisation

Healthcare. Healthcare. The Centre for Process Innovation. From innovation to commercialisation Healthcare Healthcare The Centre for Process Innovation From innovation to commercialisation The Centre for Process Innovation From innovation to commercialisation The Centre for Process Innovation (CPI)

More information

confidence. High-quality pharmaceutical market research that enables confident tactical and strategic business decisions

confidence. High-quality pharmaceutical market research that enables confident tactical and strategic business decisions act with confidence. High-quality pharmaceutical market research that enables confident tactical and strategic business decisions ISR is a full-service pharmaceutical market research firm that delivers

More information

LEEDS CITY REGION. Medical Technologies

LEEDS CITY REGION. Medical Technologies LEEDS CITY REGION Medical Technologies 1 LEEDS CITY REGION Located at the heart of the UK, the Leeds City Region represents the largest economic area in the UK outside London and the South East, with a

More information

The NENC Medical Technology Initiative: MeDConNecT North

The NENC Medical Technology Initiative: MeDConNecT North The NENC Medical Technology Initiative: MeDConNecT North Sam Eldabe Deputy Clinical Director: Clinical Research Network North East and North Cumbria dd/mm/yyyy Medical Technology Industry Why Medical Technology?

More information

Increasing Competitiveness in Clinical Research. November 2011

Increasing Competitiveness in Clinical Research. November 2011 Increasing Competitiveness in Clinical Research November 2011 Introduction The UK is witnessing a transformation in the number and qualityof clinical trials conducted in the country. This transformation

More information

BIOHEALTH INDUSTRY. Start Your Career in Wisconsin s BIOTECH AND BIOPHARMA MEDICAL DEVICE AND DIAGNOSTICS HEALTH RESEARCH INSTITUTES BIO- MANUFACTURE

BIOHEALTH INDUSTRY. Start Your Career in Wisconsin s BIOTECH AND BIOPHARMA MEDICAL DEVICE AND DIAGNOSTICS HEALTH RESEARCH INSTITUTES BIO- MANUFACTURE Start Your Career in Wisconsin s BIOHEALTH INDUSTRY BIOTECH AND BIOPHARMA MEDICAL DEVICE AND DIAGNOSTICS HEALTH RESEARCH INSTITUTES DIGITAL HEALTH BIO- MANUFACTURE Be Part of Wisconsin s BIOHEALTH INDUSTRY

More information

BIOHEALTH INDUSTRY. Start Your Career in Wisconsin s BIOTECH AND BIOPHARMA MEDICAL DEVICE AND DIAGNOSTICS HEALTH RESEARCH INSTITUTES BIO- MANUFACTURE

BIOHEALTH INDUSTRY. Start Your Career in Wisconsin s BIOTECH AND BIOPHARMA MEDICAL DEVICE AND DIAGNOSTICS HEALTH RESEARCH INSTITUTES BIO- MANUFACTURE Start Your Career in Wisconsin s BIOHEALTH INDUSTRY BIOTECH AND BIOPHARMA MEDICAL DEVICE AND DIAGNOSTICS HEALTH RESEARCH INSTITUTES DIGITAL HEALTH BIO- MANUFACTURE Be Part of Wisconsin s BIOHEALTH INDUSTRY

More information

NIHR TRANSLATIONAL RESEARCH COLLABORATION INFLAMMATORY RESPIRATORY DISEASE

NIHR TRANSLATIONAL RESEARCH COLLABORATION INFLAMMATORY RESPIRATORY DISEASE NIHR TRANSLATIONAL RESEARCH COLLABORATION INFLAMMATORY RESPIRATORY DISEASE EXPERTISE AND CAPABILITIES The TRC in Inflammatory Respiratory Disease provides cutting-edge expertise in the development of exploratory

More information

China Biopsy Devices Market Outlook to 2020

China Biopsy Devices Market Outlook to 2020 China Biopsy Devices Market Outlook to 2020 Reference Code: GDMECC0645DB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List of Figures... 5

More information

Quo vadis Medical Industry?

Quo vadis Medical Industry? Quo vadis Medical Industry? 17th December 2015 Karl Branzén Sweden has experienced the winds of change in the drug industry u In the 70s and 80s Sweden had two big medical/drug corporations Pharmacia and

More information

Brazil Gastric Balloon Procedures Outlook to 2020

Brazil Gastric Balloon Procedures Outlook to 2020 Brazil Gastric Balloon Procedures Outlook to 2020 Reference Code: GDMECC0472PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of Figures...

More information

Orphan Medicinal Products

Orphan Medicinal Products Development process of Orphan Medicinal Products 1 Did you know that... A rare disease is officially defined as a lifethreatening or chronically debilitating condition that affects no more than 5 in 10,000

More information

France Spinal Surgery Procedures Outlook to 2020

France Spinal Surgery Procedures Outlook to 2020 France Spinal Surgery Procedures Outlook to 2020 Reference Code: GDMECC0027PDB Publication Date: March 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of Figures...

More information

TRANSLATIONAL RESEARCH PARTNERSHIPS

TRANSLATIONAL RESEARCH PARTNERSHIPS TRANSLATIONAL RESEARCH PARTNERSHIPS Introduction The vision of the National Institute for Health Research (NIHR) is to improve the health and wealth of the nation through research. NIHR Translational Research

More information

Genomics and personalised medicine

Genomics and personalised medicine Genomics and personalised medicine Dr Tom Fowler, Deputy Chief Scientist & Director of Public Health WHO Symposium on the Future of Digital Health Systems in the European Region February 2019 About me

More information

Personalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies

Personalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies Personalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies The value of In Vitro Diagnostics The value of diagnostics as an integral part in the healthcare value chain Diagnostics

More information

Quo vadis Medical Industry?

Quo vadis Medical Industry? Quo vadis Medical Industry? 18th December 2014 Karl Branzén Sweden has experienced the winds of change in the drug industry In the 70s and 80s Sweden had two big medical/drug corporations Pharmacia and

More information

Japan Negative Pressure Wound Therapy (NPWT) Market Outlook to 2020

Japan Negative Pressure Wound Therapy (NPWT) Market Outlook to 2020 Japan Negative Pressure Wound Therapy (NPWT) Market Outlook to 2020 Reference Code: GDMECC0963DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables...

More information

Conduent Custom Healthcare Solution

Conduent Custom Healthcare Solution Conduent Custom Healthcare Solution Conduent HR Services has undertaken a comprehensive review of the employee benefits market, assessing all of the major providers, in order to develop our Conduent Custom

More information

INFECTIOUS DISEASES WE ARE LEADING THE WAY.

INFECTIOUS DISEASES WE ARE LEADING THE WAY. INFECTIOUS DISEASES WE ARE LEADING THE WAY. NO1 WORLD S LARGEST COLLECTION OF TICK CELL LINES OF MEDICAL AND VETERINARY IMPORTANCE ONE OF THE BIGGEST COLLECTIONS OF TROPICAL VENOMOUS SNAKES IN THE COUNTRY

More information

INFECTIOUS DISEASES WE ARE LEADING THE WAY.

INFECTIOUS DISEASES WE ARE LEADING THE WAY. INFECTIOUS DISEASES WE ARE LEADING THE WAY. NO1 WORLD S LARGEST COLLECTION OF TICK CELL LINES OF MEDICAL AND VETERINARY IMPORTANCE ONE OF THE BIGGEST COLLECTIONS OF TROPICAL VENOMOUS SNAKES IN THE COUNTRY

More information

A whole-system approach to delivering personalised medicine and health in Leeds. Mike Messenger

A whole-system approach to delivering personalised medicine and health in Leeds. Mike Messenger A whole-system approach to delivering personalised medicine and health in Leeds Mike Messenger Capacity and Resource What is the challenge? In 2016, we face the most significant challenges for a generation.

More information

GUIDE HEA

GUIDE HEA Companies are often overwhelmed by the field of digital health. From digital and med device companies to biotechnology and pharmaceutical companies, there is a struggle to cut through the noise of numerous

More information

Almac Overview.

Almac Overview. Almac Overview www.almacgroup.com 2 Welcome to Almac 3 Who is Almac? Almac is a world leading drug development & commercial services company; providing an expanding array of innovative solutions worldwide

More information

What is One Nucleus? Vision. Mission

What is One Nucleus? Vision. Mission One Nucleus What is One Nucleus? A membership organisation Funded by sponsorship, membership fees, events and projects Based in Cambridge and London but with global members Formed by merger of ERBI and

More information

University of Reading Perspective. Dr Susan Matos, Knowledge Transfer Centre University of Reading

University of Reading Perspective. Dr Susan Matos, Knowledge Transfer Centre University of Reading University of Reading Perspective Dr Susan Matos, Knowledge Transfer Centre University of Reading Overview The University of Reading s approach to Knowledge Transfer How this fits with the network Highlights

More information

The Innovative Medicines Initiative: Building new models of collaborative research across Europe

The Innovative Medicines Initiative: Building new models of collaborative research across Europe The Innovative Medicines Initiative: Building new models of collaborative research across Europe Elisabetta Vaudano IMI, Belgium www.imi.europa.eu What is IMI? An European Public-Private Partnership Focused

More information

NIHR Cambridge Clinical Research Facility

NIHR Cambridge Clinical Research Facility NIHR Cambridge Clinical Research Facility National Institute for Health Research The perfect environment for experimental medicine studies and early phase clinical trials for Life Sciences, Biotech and

More information

Advancing minimally invasive. therapeutics through novel device. development. Minima y Invasive New Technologies T H E L E O N A M. A N D H A R R Y B.

Advancing minimally invasive. therapeutics through novel device. development. Minima y Invasive New Technologies T H E L E O N A M. A N D H A R R Y B. MIN T Minima y Invasive New Technologies Advancing minimally invasive therapeutics through novel device development T H E L E O N A M. A N D H A R R Y B. C H A R I T A B L E T R U S T he Minimally Invasive

More information

Research and innovation at the heart of the NHS Sir Malcolm Grant, Chair, NHSE

Research and innovation at the heart of the NHS Sir Malcolm Grant, Chair, NHSE Research and innovation at the heart of the NHS Sir Malcolm Grant, Chair, NHSE NHS Health and Care Innovation Expo 6 September 2018 What this session is about The economic case The opportunity: research

More information

A European Public-Private Partnership! in Healthcare! Michel Goldman, MD,PhD Executive Director

A European Public-Private Partnership! in Healthcare! Michel Goldman, MD,PhD Executive Director A European Public-Private Partnership! in Healthcare! Michel Goldman, MD,PhD Executive Director ITMAT 2010, 27 October 2010 EFPIA Member Companies Participating companies (September 2010):! Innovative

More information

Version Number: 004. On: June 2018 Review Date: June 2021 Distribution: Essential Reading for: Information for: Page 1 of 10

Version Number: 004. On: June 2018 Review Date: June 2021 Distribution: Essential Reading for: Information for: Page 1 of 10 Introduction of Novel Therapeutic Interventions Policy CONTROLLED DOCUMENT CATEGORY: CLASSIFICATION: PURPOSE Controlled Number: Document Policy Governance To set out the agreed policy for the submission

More information

Research and development case study. Human health research

Research and development case study. Human health research Research and development case study Human health research November 2017 Introduction This case study on human health research is one of a series that we have developed to support and complement our published

More information

The Role of Public-Private Partnerships & Evidence Generation

The Role of Public-Private Partnerships & Evidence Generation The Role of Public-Private Partnerships & Evidence Generation Christina Donatti LLB, BSc, MSc, PsyD IMI Lead, RWE EMEA Strategic Organisation. Janssen Cilag Janssen is proud to feature artwork created

More information

Improving Pa-ent Outcomes with Research: The Appliance of Science NIHR UCL Hospitals Biomedical Research Centre

Improving Pa-ent Outcomes with Research: The Appliance of Science NIHR UCL Hospitals Biomedical Research Centre Improving Pa-ent Outcomes with Research: The Appliance of Science NIHR UCL Hospitals Biomedical Research Centre Bryan Williams MD FRCP FESC FAHA Professor of Medicine and BRC Director 29/08/2013 Creating

More information

BOARD PAPER - NHS ENGLAND. Purpose of Paper: To inform the Board of the development of an NHS England Personalised Medicine Strategy.

BOARD PAPER - NHS ENGLAND. Purpose of Paper: To inform the Board of the development of an NHS England Personalised Medicine Strategy. Paper: PB.24.09.15/05 Title: Personalised Medicine Strategy. From: Sir Bruce Keogh, National Medical Director. BOARD PAPER - NHS ENGLAND Purpose of Paper: To inform the Board of the development of an NHS

More information

North West Skills Development Network. Di Ormandy Head of North West Skills Development

North West Skills Development Network. Di Ormandy Head of North West Skills Development North West Skills Development Network Di Ormandy Head of North West Skills Development How are we Funded Via organisation subscriptions 50 % Flat rate 50% banded on staffing numbers 2,190 Band A organisation

More information

NIHR at 10: Wessex. Professor Chris Whitty Chief Scientific Adviser Department of Health

NIHR at 10: Wessex. Professor Chris Whitty Chief Scientific Adviser Department of Health NIHR at 10: Wessex Professor Chris Whitty Chief Scientific Adviser Department of Health Building on 10 remarkable years The extraordinary advances in health are based on evidence and science, properly

More information

BIOMEDICAL RESEARCH CENTRES

BIOMEDICAL RESEARCH CENTRES Introduction BIOMEDICAL RESEARCH CENTRES The vision of the National Institute for Health Research (NIHR) is to improve the health and wealth of the nation through research. This document sets out how the

More information

Personalized Healthcare Diagnostik und Therapie aus einer Hand

Personalized Healthcare Diagnostik und Therapie aus einer Hand Personalized Healthcare Diagnostik und Therapie aus einer Hand Priv.-Doz. Dr. med. Christian Meisel DVFA Life Science Conference, 17 June 2009 1 The Challenge Personalised healthcare Roche s unique position

More information

Spain Knee Replacement Procedures Outlook to 2020

Spain Knee Replacement Procedures Outlook to 2020 Spain Knee Replacement Procedures Outlook to 2020 Reference Code: GDMECC0052PDB Publication Date: March 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of Figures...

More information

SAMPLE. North America Trauma Fixation Procedures Outlook to 2020

SAMPLE. North America Trauma Fixation Procedures Outlook to 2020 North America Trauma Fixation Procedures Outlook to 2020 Reference Code: GDMECR0008PDB Publication Date: March 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List

More information

North America Surgical Sutures Market Outlook to 2020

North America Surgical Sutures Market Outlook to 2020 North America Surgical Sutures Market Outlook to 2020 Reference Code: GDMECR0234DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List of

More information

Brazil Capsule Endoscopy Procedures Outlook to 2020

Brazil Capsule Endoscopy Procedures Outlook to 2020 Brazil Capsule Endoscopy Procedures Outlook to 2020 Reference Code: GDMECC0469PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of Figures...

More information

BD Manager BROOKER. Leadership in life sciences commercialisation.

BD Manager BROOKER. Leadership in life sciences commercialisation. BROOKER C o n s u l t i n g BD Manager Leadership in life sciences commercialisation The Walter and Eliza Hall Institute of Medical Research is the oldest of its kind in Australia, with an international

More information

Research Strategy Delivering internationally excellent research for a healthy, safe and sustainable society

Research Strategy Delivering internationally excellent research for a healthy, safe and sustainable society Research Strategy 2016-2018 Delivering internationally excellent research for a healthy, safe and sustainable society Mission The College of Biomedical and Life Sciences aims to deliver internationally

More information

Speed your time to market with FDA s expedited programs

Speed your time to market with FDA s expedited programs Regulatory Sciences Expediting drug approval Speed your time to market with FDA s expedited programs The faster way to marketing submission and drug approval for serious conditions and rare diseases In

More information

Using local RWD to drive global therapeutic advancements.

Using local RWD to drive global therapeutic advancements. Using local RWD to drive global therapeutic advancements. Helsinki, 30 th Nov 2016 Mike Spencer, Head of Real World Evidence, EMEA, Janssen The following represent my own views and not necessarily those

More information

The NHS approach to personalised medicine in respiratory disease. Professor Sue Chief Scientific Officer for England

The NHS approach to personalised medicine in respiratory disease. Professor Sue Chief Scientific Officer for England The NHS approach to personalised medicine in respiratory disease Professor Sue Hill @CSOSue Chief Scientific Officer for England Jul 2017 Genomics is probably the biggest breakthrough in the last 50 years.

More information

Job description and person specification

Job description and person specification Job description and person specification Position Job title Head of Genomics Unit Directorate Finance, Commercial and Specialised Commissioning Pay band AFC Band 9 Responsible to Director of Strategy and

More information

EU scientific regulatory support mechanisms and initiatives for innovation in drug development: the EMA perspective

EU scientific regulatory support mechanisms and initiatives for innovation in drug development: the EMA perspective EU scientific regulatory support mechanisms and initiatives for innovation in drug development: the EMA perspective FAMHP Workshop, Brussels, 2 nd May 2016 Presented by Zahra Hanaizi Product Development

More information

Innovation & Healthy Lifestyles An economic challenge for all of us. Michael Wood NHS Local Growth Advisor NHS Confederation 30 November 2016

Innovation & Healthy Lifestyles An economic challenge for all of us. Michael Wood NHS Local Growth Advisor NHS Confederation 30 November 2016 Innovation & Healthy Lifestyles An economic challenge for all of us Michael Wood NHS Local Growth Advisor NHS Confederation 30 November 2016 NHS Local Growth Advisor my role Aim help health economies engage

More information

Genomics in the NHS. Professor Sue Chief Scientific Officer for England

Genomics in the NHS. Professor Sue Chief Scientific Officer for England Genomics in the NHS Professor Sue Hill @CSOSue Chief Scientific Officer for England Nov 2017 100,000 Genomes Project: overview PRINCIPLES 100,000 genomes from Rare Disease (families) & Cancer (people &

More information

Helping your employees to get. healthier

Helping your employees to get. healthier Helping your employees to get healthier employee health is about so many things At Nuffield Health, we believe the real health of a company should be judged not just on its revenues but on the health and

More information

MAKING OUTCOME-BASED PAYMENTS A REALITY IN THE NHS RESEARCH STUDY: PHASE INTRODUCTION. Research Brief

MAKING OUTCOME-BASED PAYMENTS A REALITY IN THE NHS RESEARCH STUDY: PHASE INTRODUCTION. Research Brief MAKING OUTCOME-BASED PAYMENTS A REALITY IN THE NHS RESEARCH STUDY: PHASE 1 1.0 INTRODUCTION Cancer Research UK (CRUK) believes cancer patients should have access to the best, evidence-based innovative

More information

Personalized. Health in Canada

Personalized. Health in Canada Personalized Health in Canada Canadian Institutes of Health Research Personalized Medicine Signature Initiative 2010-2013 0 Dr. Morag Park CIHR Institute of Cancer Research Dr. Paul Lasko CIHR Institute

More information

Translational Research

Translational Research Translational Research Paddy Johnston Chair, MRC Translational Research Overview Group October 2012 Translational Research Strategy and its delivery To accelerate patient benefit and increase economic

More information

Engagement with stakeholders

Engagement with stakeholders Engagement with stakeholders 2 nd International Awareness Session - The EU medicines regulatory system and the European Medicines Agency Presented by Juan Garcia Burgos and Marie-Helene Pinheiro on 8 March

More information

Adis Journals and Newsletters The premier collection of drug-focused medical journals

Adis Journals and Newsletters The premier collection of drug-focused medical journals adis.com Adis Journals and Newsletters The premier collection of drug-focused medical journals An invaluable resource for all involved in medical research, practice or teaching, drug regulation or reimbursement,

More information

Research Strategy

Research Strategy V1.3, October 2013 Research Strategy 2013 17 Page 1 of 15 CONTENTS Page Executive summary 3 1. Introduction and strategic context 4 2. CCC s current research portfolio 6 3. Research strategic goals 2011

More information

Healthcare Technologies Strategy

Healthcare Technologies Strategy ENGINEERING AND PHYSICAL SCIENCES RESEARCH COUNCIL Healthcare Technologies Strategy TOWN MEETING, APRIL 14 th 2015 Aug 2014 Engineering and Physical Sciences Research Council Healthcare Technologies 29%of

More information

Cancer Programme Manager. Full time (37.5 hours per week)

Cancer Programme Manager. Full time (37.5 hours per week) Job title Salary Hours Base Accountable to Cancer Programme Manager 33,222 to 59,964 (dependent on experience) Full time (37.5 hours per week) Cambridge Director of Transformation ABOUT EASTERN AHSN The

More information

Innovative Medicines Initiative (IMI) Future funding opportunities. Catherine Brett, IMI Conferencia H2020 y Salud Madrid, Spain 8 November 2017

Innovative Medicines Initiative (IMI) Future funding opportunities. Catherine Brett, IMI Conferencia H2020 y Salud Madrid, Spain 8 November 2017 Innovative Medicines Initiative (IMI) Future funding opportunities Catherine Brett, IMI Conferencia H2020 y Salud Madrid, Spain 8 November 2017 Outline What is IMI and why do we need it? How does IMI work?

More information

A SMALL FISH IN A BIG POND MATCHING THE NEEDS OF SMALLER PHARMA SPONSORS

A SMALL FISH IN A BIG POND MATCHING THE NEEDS OF SMALLER PHARMA SPONSORS A SMALL FISH IN A BIG POND MATCHING THE NEEDS OF SMALLER PHARMA SPONSORS WITH THE RIGHT CRO DR SALLY ADAMS DEVELOPMENT DIRECTOR SCANCELL LTD 1 SCANCELL LTD Founded in 1997 as a spin-out from the University

More information

COMPLETE A FIXED COST. insurance-backed employment law protection scheme for employers.

COMPLETE A FIXED COST. insurance-backed employment law protection scheme for employers. COMPLETE A FIXED COST insurance-backed employment law protection scheme for employers EMPLOYMENT LAW CHANGES SO FREQUENTLY... and business life is so demanding, that s why employers often find it difficult

More information

South Korea Ultrasound Systems Market Outlook to 2020

South Korea Ultrasound Systems Market Outlook to 2020 South Korea Ultrasound Systems Market Outlook to 2020 Reference Code: GDMECC0289DB Publication Date: March 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List of Figures...

More information

Australia: A Dynamic Environment for Conducting Clinical Trials

Australia: A Dynamic Environment for Conducting Clinical Trials Australia: A Dynamic Environment for Conducting Clinical Trials MTPConnect s goal is to accelerate the growth of Australia s MTP sector Industry Associations Governments Universities Researchers Investors

More information

SWELIFE CALL IN WIDESPREAD DISEASES Karin Agerman

SWELIFE CALL IN WIDESPREAD DISEASES Karin Agerman SWELIFE CALL IN WIDESPREAD DISEASES 2016-2017 Karin Agerman 2016-01-11 Strategic innovation areas To meet global competition and to help solve global societal challenges Cross-border collaboration for

More information

NPIMR. Progress for Patients.

NPIMR. Progress for Patients. www.npimr.org Our vision is to be recognised as a leading biomedical research and service organisation that seeks to radically improve outcomes and maximise benefits for patients and the wider NHS. We

More information

Belgium, a European leader in clinical trials

Belgium, a European leader in clinical trials Belgium, a European leader in clinical trials An attractive country for clinical trials to test innovative medicines In Europe it is nearly impossible to find other countries with as many clinical trials

More information

BRIC Surgical Sutures Market Outlook to 2020

BRIC Surgical Sutures Market Outlook to 2020 BRIC Surgical Sutures Market Outlook to 2020 Reference Code: GDMECR0270DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 5 1.2 List of Figures...

More information

Personal Health Budgets

Personal Health Budgets Personal Health Budgets Health and social care systems support Personal Health Budgets Effective delivery of Personal Health Budgets (PHBs) is crucial for Clinical Commissioning Groups (CCGs) to achieve

More information

Roche in Australia Innovation Leader

Roche in Australia Innovation Leader Roche in Australia Innovation Leader About Roche Innovation: it s in our DNA 7,000,874 hours of work 6,587 experiments 423 researchers 1 drug For nearly 120 years, Roche has been committed to improving

More information

April 7, Dear Ms Närhi,

April 7, Dear Ms Närhi, European Commission DG Enterprise & Industry Unit F2 Pharmaceuticals Legal Proposal on Information to Patients ulla.narhi@ec.europa.eu 45 Avenue d Auderghem, Office 10/93 B 1049 Brussels - Belgium April

More information

The Birmingham Institute of Translational Medicine. Professor Charles Craddock

The Birmingham Institute of Translational Medicine. Professor Charles Craddock The Birmingham Institute of Translational Medicine Professor Charles Craddock Challenges in delivering on a translational medicine agenda After decades of investment in basic research it is now apparent

More information

THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 118 PATIENT GROUPS with an interest in RESPIRATORY CONDTIONS

THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 118 PATIENT GROUPS with an interest in RESPIRATORY CONDTIONS THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 118 PATIENT GROUPS with an interest in RESPIRATORY CONDTIONS PUBLISHED OCTOBER 2016 [Question to respondents: Which companies have the best record

More information

Regenerative Medicine Business Models

Regenerative Medicine Business Models Regenerative Medicine Business Models Geoff Banda, Joyce Tait and James Mittra 23 May 2017 1 Business Models Value Chains Innovation Ecosystems 10 Case studies in the UK Private Firms (7) Public Organisations

More information

BUSINESS OBJECTIVES AND FUTURE PLANS

BUSINESS OBJECTIVES AND FUTURE PLANS BUSINESS OBJECTIVES AND STRATEGIES Our objectives are to consolidate and strengthen our position to become one of the leading distributors of pharmaceutical products in Zhejiang province. To further develop

More information

EMERGING OPPORTUNITIES

EMERGING OPPORTUNITIES AUGUST 2015 to NOVEMBER 2015 EMERGING OPPORTUNITIES 2015 Proudly sponsored by Page 1 Page 2 Contents ABOUT KIWINET... 4 CONTACT... 4 ABOUT THIS DOCUMENT... 5 Pouchitis... 6 Alzheimer s Therapeutic... 7

More information

a pioneering & a a vibrant science & technology company

a pioneering & a a vibrant science & technology company WE ARE WE ARE a pioneering & a a vibrant science & technology company We are Merck a leading science and technology company working in healthcare, life science and performance materials. From the screen

More information

May Patient Reported Outcomes: Strategies for gaining or expanding market access ES SAMPLE PAGES SA. A FirstWord ExpertViews Dossier Report

May Patient Reported Outcomes: Strategies for gaining or expanding market access ES SAMPLE PAGES SA. A FirstWord ExpertViews Dossier Report A FirstWord ExpertViews Dossier Report Published Copyright 2016 Doctor s Guide Publishing Limited All rights reserved. No part of this publication may be reproduced or used in any form or by any means

More information

Improved analysis of genetic testing could lead to more patients with inherited conditions being successfully diagnosed

Improved analysis of genetic testing could lead to more patients with inherited conditions being successfully diagnosed PRESS RELEASE 17 August 2016 Improved analysis of genetic testing could lead to more patients with inherited conditions being successfully diagnosed A groundbreaking study, led by experts from Royal Brompton

More information

MEETING THE INCREASING REQUIREMENTS FOR HUMAN FACTORS CONSIDERATIONS

MEETING THE INCREASING REQUIREMENTS FOR HUMAN FACTORS CONSIDERATIONS MEETING THE INCREASING REQUIREMENTS FOR HUMAN FACTORS CONSIDERATIONS Human factors engineering (HFE) is now an essential requirement for all new drug delivery combination product approvals to ensure devices

More information

NEW DRUG FORMULATIONS TO BOOST FIGHT AGAINST RESPIRATORY ILLNESSES AND ANTIBIOTIC-RESISTANT SUPERBUGS

NEW DRUG FORMULATIONS TO BOOST FIGHT AGAINST RESPIRATORY ILLNESSES AND ANTIBIOTIC-RESISTANT SUPERBUGS MEDIA RELEASE FOR IMMEDIATE RELEASE 15 September 2014 NEW DRUG FORMULATIONS TO BOOST FIGHT AGAINST RESPIRATORY ILLNESSES AND ANTIBIOTIC-RESISTANT SUPERBUGS A team from A*STAR s Institute of Chemical and

More information

Commercialising early stage agbiotechnology from academia: challenges and opportunities. Rupert Osborn CEO, IP Pragmatics Ltd March 2011

Commercialising early stage agbiotechnology from academia: challenges and opportunities. Rupert Osborn CEO, IP Pragmatics Ltd March 2011 Commercialising early stage agbiotechnology from academia: challenges and opportunities Rupert Osborn CEO, IP Pragmatics Ltd March 2011 Overview Introduction to IP Pragmatics Agbiotechnology crop market

More information

Leading the world in novel adult stem cell therapies Half-Year Financial Results

Leading the world in novel adult stem cell therapies Half-Year Financial Results Leading the world in novel adult stem cell therapies 2013 Half-Year Financial Results CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation, including any comments made during or following

More information

France Pressure Relief Devices Market Outlook to 2020

France Pressure Relief Devices Market Outlook to 2020 France Pressure Relief Devices Market Outlook to 2020 Reference Code: GDMECC0869DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of

More information

EU Big Data Initiatives

EU Big Data Initiatives European Network of Excellence for Big Data in Hematology, consisting of 51 partners from 11 countries. Aliki Taylor, HARMONY Alliance Partner Director Global Health Outcomes, Takeda EU Big Data Initiatives

More information

Coast to Capital LEP. Follow us on Twitter Website -

Coast to Capital LEP. Follow us on Twitter Website - Coast to Capital LEP 76.8% employment rate 6th Most prosperous region in the UK 1.9 million people 20% of SE economy 61,000 Average GVA per employee 48.5 bn GVA 84,000 SME businesses in the area Housing

More information

- OMICS IN PERSONALISED MEDICINE

- OMICS IN PERSONALISED MEDICINE SUMMARY REPORT - OMICS IN PERSONALISED MEDICINE Workshop to explore the role of -omics in the development of personalised medicine European Commission, DG Research - Brussels, 29-30 April 2010 Page 2 Summary

More information

The International Consortium for Personalised Medicine

The International Consortium for Personalised Medicine The International Consortium for Personalised Medicine Mairead O Driscoll Alliance for Biomedical Research in Europe, 8 November 2017 Personalised Medicine A definition Characterisation of individuals

More information

The NIHR. NIHR: health research in Professor Stephen Smye Specialty Cluster Lead, NIHR CRN, King s College London. Clinical Research Network

The NIHR. NIHR: health research in Professor Stephen Smye Specialty Cluster Lead, NIHR CRN, King s College London. Clinical Research Network The NIHR NIHR: health research in 2030 Professor Stephen Smye Specialty Cluster Lead, NIHR CRN, King s College London Why? https://www.bhf.org.uk/publications/statistics/ trends-in-coronary-heart-disease-1961-2011

More information